Grown Rogue International (GRUSF) Receivables (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Receivables came in at $3.2 million in Q1 2026, up 130.86% year-on-year from $1.4 million in Q1 2025, and up 11.39% quarter-over-quarter from $2.9 million in Q4 2025.
Grown Rogue International (GRUSF) Receivables (2009 - 2026) Analysis & Trends
Grown Rogue International's Receivables history runs 18 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- On a quarterly basis, Receivables rose 130.86% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 130.86% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, up 149.34% from the prior year.
- Receivables rose to $3.2 million in Q1 2026 per GRUSF's latest filing, from $2.9 million in the prior quarter.
- Across five years, Receivables topped out at $2020.9 billion in Q3 2025 and bottomed at -$681152.8 in Q4 2022.
- The 5-year median for Receivables is $1.9 million (2024), against an average of $144.4 billion.
- Across the five-year window, Receivables sank 107.82% in 2022 and soared 103586638.4% in 2025, its largest moves.
- Year by year, Receivables stood at -$681152.8 in 2022, then jumped by 509.85% to $2.8 million in 2023, then sank by 59.05% to $1.1 million in 2024, then surged by 154.41% to $2.9 million in 2025, then gained by 11.39% to $3.2 million in 2026.
- Per Business Quant, the three latest GRUSF Receivables figures stand at $3.2 million (Q1 2026), $2.9 million (Q4 2025), and $2020.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 2.99 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.46 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 312.00 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.29 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.58 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 768.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.15 Bn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 3.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.24 Mn |
| Dec 31, 2025 | 2.91 Mn |
| Sep 30, 2025 | 2,020.92 Bn |
| Jun 30, 2025 | 2.10 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 1.14 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 1.99 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Oct 31, 2023 | -343,277.59 |
| Apr 30, 2023 | 1.78 Mn |
| Jan 31, 2023 | 1.28 Mn |
| Oct 31, 2022 | -681,152.77 |
| Oct 31, 2021 | -327,768.09 |
| Apr 30, 2021 | 372,663.00 |
| Jan 31, 2021 | 238,987.00 |
| Oct 31, 2020 | 175,621.00 |
| Jul 31, 2020 | 269,216.00 |
| Apr 30, 2020 | 176,547.00 |